INDOLENT LYMPHOMAS Flashcards

1
Q

what is lymphoproliferative disease?

A

neoplastic, clonal proliferation of lymphoid cells
- a cancer of white blood cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what does lymphoproliferative disease usually affect?

A

lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

where can lymphoproliferative disease be?

A

Can be Extranodal – Bone Marrow / Liver / Spleen / Anywhere

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the two types of non Hodgkins lymphoma?

A

agressive
indolent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

indolent non H lymphoma

A

slowly growing and advanced at presentation
don’t require treatment
usually incurable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

aggressive non H lymphoma

A

grow faster r
chemo sensitive
curable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

H lymphoma

A

tends to be in younger people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

how is NHL classified?

A

B cell - 90%
T cell- 10%
NK cell- <1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the different subtypes of indolent lymphoma?

A
  • follicular
  • marginal one lymphoma
    -mantle cell lymphoma
  • CLL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what does the cause of dead tend to be with people who have indolent lymphoma?

A

-Cause of death usually related to Lymphoma and not anything else

  • Relapse/Refractory disease;
    -High grade transformation (Richter’s)*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the cause of indolent lymphomas? ( aetiology)

A
  • most cases is unknown
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the Risk factors for indolent lymphomas?

A
  • primary immunodeficiency-
    e.g. Wiscott-Aldrich Syndrome; Common Variable Immunodeficiency
  • secondary immunodeficiency-
    e.g. HIV; Recipients of Transplant
  • infection
    e.g. EBV; HTLV-1; Helicobacter Pylori
  • autoimmune disorders
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

describe the clinical presentation of someone with indolent lymphomas

A

-painless lymphadenopathy- ( lump)

-Association with B-Symptoms – Fevers, Night Sweats and Weight Loss

-?Bone Marrow involvement – ?Leukaemic component- low blood count

-Autoimmune Phenomena

-Compression Syndromes

-Organ Involvement e.g. Skin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what investigations would you do for indolent lymphomas?

A

Lymph Node Biopsy – Core Needle Biopsy/ Excision Node Biopsy (NOT FNA)

?Bone Marrow Biopsy

Staging
lugano (Update on Ann Arbor) Staging Classification typical for most Indolent lymphomas
Requires Imaging – CT Neck/Thorax/Abdomen/Pelvis or PET-CT

Bloods
Bone Marrow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what treatment would you do for indolent lymphomas? ( name them)

A

-Watch and Wait / Active Surveillance
-Radiotherapy
-Chemoimmunotherapy +/- maintenance
-Small molecules inhibitors / Novel therapies
-Bi-Specific T-Cell engaging Antibodies and Chimeric Antigen Receptor T Cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe the Watch and Wait / Active Surveillance treatment method

A

-Asymptomatic, advanced stage patients

-Follow up regularly

-No compromise in overall survival

17
Q

describe radiotherapy as a treatment method

A
  • Local Control (Palliative)
  • potentially can be Curative
18
Q

describe Chemoimmunotherapy +/- maintenance as a treatment method

A

-Alkylating agents e.g. Chlorambucil, Bendamustine, Cyclophosphamide

  • Anthracyclines e.g. Doxorubicin - Vina Alkaloids e.g. Vincristine
  • Corticosteroids
  • Combinations

-Monoclonal Antibodies
-Anti-CD20 e.g. Rituximab; Obinutuzumab

- Maintenance therapy – Follicular Lymphoma; Mantle Cell Lymphoma

19
Q

describe Bi-Specific T-Cell engaging Antibodies and Chimeric Antigen Receptor T Cells as a treatment method

A

Emerging therapies in indolent lymphoma

CAR-T NICE Approved for BTKi failures in Mantle Cell Lymphoma

Mosunetuzumab – Trials in FL / MCL / DLBCL

20
Q

describe Small molecules inhibitors / Novel therapies as a treatment method

A

Brutons Tyrosine Kinase Inhibitors

BCL2 Inhibitors

IMiDs